title: Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
abstract: Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines the rationale for developing new combined therapeutic approaches, and describes the state of the art of the various potential strategies and the promising research perspectives.
authors.affiliation: Department of Hematology and Oncological Sciences "L.A. Seragnoli", S. Orsola-Malpighi Hospital, University of Bologna, Italy. maria.pantaleo@unibo.it
authors.forename: Maria Abbondanza
authors.initials: MA
authors.lastname: Pantaleo
authors.forename: Margherita
authors.initials: M
authors.lastname: Nannini
authors.forename: Monica
authors.initials: M
authors.lastname: Di Battista
authors.forename: Fausto
authors.initials: F
authors.lastname: Catena
authors.forename: Guido
authors.initials: G
authors.lastname: Biasco
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib